(Q33329325)

25 July 2017

Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics (English)

1 reference

25 July 2017

1 reference

1 reference

1 reference

G T Everson

1

1 reference

25 July 2017

D M Jensen

2

1 reference

25 July 2017

J R Craig

3

1 reference

25 July 2017

D J van Leeuwen

4

1 reference

25 July 2017

V G Bain

5

1 reference

25 July 2017

M N Ehrinpreis

6

1 reference

25 July 2017

D Albert

7

1 reference

25 July 2017

T Joh

8

1 reference

25 July 2017

K Witt

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

25 July 2017

1 reference

25 July 2017

30

1 reference

25 July 2017

271-276

1 reference

25 July 2017

1

1 reference

Clinical outcomes after transfusion-associated hepatitis C.

25 July 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Therapy of hepatitis C: patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Clinical toxicity of the interferons.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Relationship between biochemical and virological responses to interferon therapy in chronic hepatitis C infection. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510300116

7 January 2021

Identifiers

DOI

10.1002/HEP.510300116

1 reference

25 July 2017

1 reference